Spirit Scientific Wins Awards at 2025 Taiwan Innotech Expo, Highlighting Precision Regenerative Medicine Innovations
Spirit Scientific (7790), a company focusing on precision regenerative medicine, recently showcased two innovative patented technologies at the 2025 Taiwan Innotech Expo (TIE): “A Growth Factor-Rich Dry Powder for Use in Alleviating Inflammation or Injury” and “A Platelet-Containing Composition and Method for Preparing the Same.” Both technologies earned the company Bronze Medals in the invention competition.
Spirit Scientific stated that both patents are based on the company’s core Biological Material Lyophilization Technology (BMLT). This achievement demonstrates Spirit Scientific’s success in continuously expanding its preparation services for diverse materials and their clinical applications, starting from platelet lyophilization.
The company further noted that the Taiwan Innotech Expo, co-hosted by 11 government ministries, including the Ministry of Economic Affairs, the National Science and Technology Council, and the Ministry of Health and Welfare, featured the theme “AI-Driven Cross-Domain Innovation, Intelligent Future” this year. The expo gathered over a thousand innovative technologies and serves as a vital platform for domestic and international technology exchange.
Additionally, Spirit Scientific participated in the 88th Annual Meeting of the Taiwanese Orthopaedic Association from October 25th to 26th. At the event, the company engaged in in-depth discussions with numerous orthopedic authorities regarding the challenges of traditional Platelet-Rich Plasma (PRP) in clinical applications, specifically addressing pain points such as concentration instability and the inability to achieve standardized quantification.
Notably, a recent meta-analysis published in The American Journal of Sports Medicine in 2025 suggested that insufficient platelet count might be one factor contributing to the ineffectiveness of PRP treatment.
In response to this, Spirit Scientific’s PLT Platelet Lyophilization Preparation Service aims to overcome the limitations of traditional PRP therapy. Utilizing proprietary patented technology and a standardized, precise process, the core objective is to provide an innovative solution that is dosed and quantified, safe, reliable, capable of long-term storage at room temperature, and offers flexible treatment scheduling.
Furthermore, building upon the foundation of PLT, Spirit Scientific has launched its derivative preparation service, “PLTgel™.” The company explained that this service not only retains the advantage of PLT’s fixed dosing and quantification but also extends the release time of growth factors through an innovative slow-release gel formulation. This provides a more precise and effective regenerative medicine option for orthopedic applications requiring prolonged tissue repair, such as large-area soft tissue injuries and degenerative arthritis.
Source: https://news.gbimonthly.com/tw/article/show.php?num=81073
